Hepatitis, HIV-1 Infection
Conditions
Brief summary
Early identification of acute HCV infection is essential to prevent chronic infections and the long-term liver disease complications that may occur. Early identification and treatment of HCV during the acute phase can result in significantly higher response rates with shorter durations of therapy. Pegylated-interferon alfa (PEG-IFN) was the typical treatment for HCV infection. Participants subcutaneously inject PEG-IFN where the average duration of treatment was approximately 20 weeks. With the advancement of direct-acting antivirals (DAAs), it was possible to see if a new DAA might be non-inferior compared to (PEG-IFN). The study was designed to see if a fixed-dose combination tablet can replace the old HCV treatments by being more effective, safer and better tolerated in HIV-infected participants with new HCV infection. The study was a Phase I, open-label, two cohort clinical trial, in which 44 acutely HCV-infected HIV-1 positive participants were enrolled. Participants in each cohort were evaluated in two steps: on treatment (Step 1) and follow-up after discontinuing study treatment (Step 2). The cohorts were enrolled sequentially. Participants in Cohort 1 were enrolled and administered oral Sofosbuvir (SOF) in combination with weight-based ribavirin (RBV). Participants in Cohort 2 were enrolled and administered an oral fixed dose combination of Ledipasvir/Sofosbuvir (LDV/SOF).
Detailed description
The first cohort opened with SOF/RBV treatment for 12 weeks and accrued 17 participants. All participants under Cohort 1 were to visit the clinical site at weeks 0, 1, 2, 4, 8, and 12 when on treatment (Step 1), then visit the clinical site again at 2, 4, 8, 12 and 24 weeks during follow-up after discontinuing study treatment (Step 2). The second cohort opened for an 8-week treatment of LDV/SOF and included at least 27 subjects. All participants under Cohort 2 were to visit the clinical site at weeks 0, 1, 2, 4, and 8 when on treatment (Step 1), then visit the clinical site again at 2, 4, 8, 12 and 24 weeks during follow-up after discontinuing study treatment (Step 2). Both cohorts were monitored for safety and HCV viral load response while the participants were on treatment. The primary objective did not compare the cohorts together; instead, each study cohort was formally assessed for efficacy with sustained virologic response 12 weeks after treatment based on non-inferiority criteria compared to a historical SVR rate of 60% separately.
Interventions
DRUGSofosbuvir
Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
DRUGRibavirin
Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
A5327 Eligibility Criteria (Cohort 1 and Cohort 2) Step 1 inclusion criteria for both cohorts (Cohort 1 and Cohort 2) * HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 p24 antigen, or plasma HIV-1 RNA viral load. \[NOTE: The term licensed refers to a FDA-approved kit, which is required for all IND studies.\] WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load. * A documented confirmation of acute HCV infection within 6 months prior to A5327 entry or HCV reinfection as described below: 1. Acute HCV infection was defined as meeting one of the following criteria and exclusion of other causes of acute hepatitis: * New (\<24 weeks prior to initial A5327 entry) ALT elevation to ≥5X upper limit of normal (ULN) OR \>250 U/L in patients with documented normal ALT in the preceding 12 months or ≥10X ULN OR \>500 U/L in patients with abnormal or no measured ALT baseline in the preceding 12 months with detectable HCV RNA excluding those with any prior positive anti-HCV. OR * Detectable HCV RNA with prior negative anti-HCV Ab or undetectable HCV RNA within the preceding 6 months. 2. Acute HCV reinfection was defined by documentation of clearance of prior infection (as evidenced by positive anti-HCV Ab) either spontaneously or after treatment with two negative HCV RNA a minimum of 6 months apart AND meeting one of the following criteria in addition to exclusion of other causes of acute hepatitis: * New (\<24 weeks prior to initial A5327 entry) ALT elevation to ≥5X ULN OR \>250 U/L in patients with documented normal ALT in the preceding 12 months or ≥10X ULN OR \>500 U/L in patients with abnormal or no measured ALT baseline in the preceding 12 months with detectable HCV RNA. OR * Positive HCV RNA with prior negative HCV RNA within the preceding 6 months. * HCV RNA confirmed to be detectable \>12 weeks after first laboratory evidence of acute HCV and still within the \<24 week from first laboratory evidence of acute HCV infection window. First laboratory evidence of infection was defined as date of first elevated liver enzymes or date of first serologic evidence of HCV seroconversion and/or viremia (whichever occurs first). \[NOTE: If the screening visit occurred less than 12 weeks from the first laboratory evidence of infection, then the participant was required a pre-entry study visit to confirm detectable HCV RNA at least 12 weeks from the first laboratory evidence of infection had passed. It was optimal for this pre-entry visit to occur as close as possible to 12 weeks from first laboratory evidence to ensure timely treatment. Potential participants who entered screening but who had an undetectable HCV RNA (\<LLOQ TND) at the pre-entry visit (when required) exhibited evidence of possible spontaneous clearance and will not meet the entry criteria.\] * Body mass index (BMI) ≥ 18 kg/m\^2 * Screening electrocardiogram (ECG) without clinically significant abnormalities as determined by the investigator. * Willing and able to provide written informed consent. * Men and women age ≥ 18 years. * All participants agreed not to participate in a conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). \[NOTE: Female candidates who were pregnant or breastfeeding were not eligible. A male candidate who had a pregnant female partner was not eligible for the study.\] * When participating in sexual activity that could lead to pregnancy, all participants must agree to use at least two reliable forms of contraceptive simultaneously while receiving protocol-specified medications, and for 6 months after stopping the medications. Such methods included: * Condoms (male or female) with or without a spermicidal agent * Diaphragm or cervical cap with spermicide * Intrauterine device (IUD) * Tubal ligation * Hormone-based contraceptive (except those containing drospirenone) \[NOTE: Providers and participants were advised that not all contraceptive choices listed above can prevent HIV transmission and that some may actually increase the risk of HIV acquisition. Study participants who were sexually active with HIV-1 negative or unknown HIV-1 serostatus partners were advised that they needed to consider effective strategies for reducing the risk of HIV transmission, as well as meeting the requirement for effective contraception during their participation in the study. Study participants discussed contraceptive choices and HIV risk reduction methods with their health care provider.\] * Participants who were not of reproductive potential (women who had been post-menopausal for at least 24 consecutive months or had undergone hysterectomy and/or bilateral oophorectomy or salpingectomy or men who had documented azoospermia or undergone vasectomy) were eligible without requiring the use of contraceptives. Acceptable documentation of sterilization and menopause was specified below. * Written or oral documentation communicated by clinician or clinician's staff of one of the following: * Physician report/letter * Operative report or other source documentation in the patient record (a laboratory report of azoospermia was required to document successful vasectomy) * Discharge summary * Follicle stimulating hormone-release factor (FSH) measurement elevated into the menopausal range as established by the reporting laboratory. * Intention to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments. Step 1 inclusion criteria for Cohort 1 only * HIV-1 ARV therapy fell into one of the following criteria: 1. ARV untreated, for example due to (1) lack of indication per provider (CD4 T-cell count \>500 cells/mm3) or (2) decision by provider and participant to defer ARV therapy during the study drug dosing period (8 or 12 weeks), or (3) elite controller (CD4+ \>200 cells/mm3). OR 2. On a stable, protocol-approved (didanosine (ddI), stavudine (d4T), zidovudine (ZDV) excluded), ARV regimen for \>8 weeks prior to screening with a CD4 T-cell count \>200 cells/mm3 and a documented plasma HIV-1 RNA level \<50 copies/mL or \< lower limit of quantification (LLOQ) of local assay if LLOQ is \>50 copies/mL by any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent ≥ 8 weeks preceding the A5327 screening visit. HIV-1 RNA levels should be within 1 year of the screening visit. Screening HIV-1 RNA must be \< 50 copies/mL as measured by any local laboratory using an FDA-approved assay. * Candidates must have had the following laboratory parameters within 10-42 days prior to study entry: 1. Hemoglobin ≥ 12 g/dL for male, ≥11 g/dL for female participants 2. International normalized ratio (INR) ≤1.5 x ULN unless participant was known hemophilia or was stable on an anticoagulant regimen affecting INR 3. Albumin ≥ 3 g/dL 4. Creatinine clearance (CrCl) ≥ 60 mL/min, as calculated by the Cockcroft-Gault equation (refer to section 6.3.5 for calculator utility link) * Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who had not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy) must had a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL performed during screening, within 48 hours prior to study entry. Step 1 inclusion criteria for Cohort 2 only * HCV genotype 1a, 1b, or 4 infection with source documentation from a CLIA-approved laboratory (or its equivalent). \[NOTE: Those with mixed 1a/b genotype were classified as 1a.\] * HIV-1 ARV therapy fell into one of the following criteria: 1. ARV untreated, for example due to (1) lack of indication per provider (CD4 T-cell count \>500 cells/mm3) or (2) decision by provider and participant to defer ARV therapy during the study drug dosing period (8 or 12 weeks), or (3) elite controller (CD4+ \>200 cells/mm3). OR 2. On a stable, protocol-approved ARV regimen (the following ARVs are not allowed: ddI, d4T, and TPV/r) for \>8 weeks prior to screening with a CD4 T-cell count \>200 cells/mm3 and a documented plasma HIV-1 RNA level \<50 copies/mL or \<LLOQ of local assay if LLOQ is \>50 copies/mL by any laboratory that had a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent ≥ 8 weeks preceding the A5327 screening visit. HIV-1 RNA levels should be within 1 year of the screening visit. Screening HIV-1 RNA must be \<50 copies/mL as measured by any local laboratory using an FDA-approved assay. * Candidates must have had the following laboratory parameters within 10-42 days prior to study entry: 1. Hemoglobin ≥9 g/dL for male and female participants 2. International normalized ratio (INR) ≤1.5 x ULN unless participant had known hemophilia or wass stable on an anticoagulant regimen affecting INR 3. Albumin ≥3 g/dL 4. Creatinine clearance (CrCl) ≥60 mL/min, as calculated by the Cockcroft-Gault equation (refer to section 6.3.5 for calculator utility link) * Female participants of reproductive potential (defined as women who had not been post-menopausal for at least 24 consecutive months, ie, who had menses within the preceding 24 months, or women who had not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy) must had a negative serum or urine pregnancy test within 48 hours prior to study entry by any laboratory or clinic that had a CLIA certificate or its equivalent, or was using a point-of-care (POC)/CLIA-waived test. The serum, urine or POC pregnancy test must had a sensitivity of at least 25 mIU/mL. Step 1
Exclusion criteria
for both cohorts (Cohort 1 and Cohort 2) * Received investigational drug or device within 60 days prior to study entry. * Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, α1 antitrypsin deficiency, primary sclerosing cholangitis). * Presence of active or acute AIDS-defining opportunistic infections within 30 days prior to study entry. \[NOTE: A list of AIDS-defining opportunistic infections as defined by the CDC, can be found in Appendix B of the following document: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm\] * Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics, antivirals, or antifungals within 30 days prior to study entry. * Infection with hepatitis B virus (HBV) defined as HBsAg positive. * Evidence of acute hepatitis A infection defined as HAV IGM positive. * Chronic use of systemically administered immunosuppressive agents (eg, prednisone equivalent \> 10 mg/day). * History of solid organ transplantation. * Current or prior history of clinical hepatic decompensation (eg, ascites, encephalopathy or variceal hemorrhage). * History of a gastrointestinal disorder (or post operative condition) that could interfere with the absorption of the study drug. * History of significant or symptomatic pulmonary disease, cardiac disease, or porphyria. * History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy. * History of clinically significant illness or any other major medical disorder that may interfere with participant treatment, assessment, or compliance with study requirements, which may included active drug or alcohol use or dependence. * Use of any prohibited concomitant medications within 30 days prior to study entry. * Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable. \[NOTE: Participants with early infection, defined as within the first 6 months of infection and with a positive HIV antibody, should be discussed with the A5327 protocol core team. These participants may be considered for inclusion in the study on a case by case basis with the specific documented approval of the protocol chairs.\] Step 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 (SVR12) | At 12 weeks after date of last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | SVR12 was defined as HCV RNA undetectable less than the lower limit of quantification, Target Not Detected (\<LLOQ TND) of the assay at 12 weeks after date of last dose of study treatment. For both Cohort 1 and Cohort 2, the 12 week measurement used for determining SVR12 was the measurement obtained closest to 84 days (i.e. 12\*7 days), within the window 79 to 112 days inclusive. If a participant did not have an HCV RNA measurement within this window, then the participant was considered as having detectable HCV RNA at 12 weeks unless the preceding and subsequent HCV RNA measurements were both undetectable (\<LLOQ TND). A two-sided 90% confidence interval was calculated for this percentage using the Blyth-Still-Casella method. |
| Percentage of Participants With an Occurrence of a Grade ≥ 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE. | From initiation of study treatment to 28 days after last dose of study treatment. The duration for study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | Any adverse event occurring after initiation of study treatment through to 28 days after the date of last dose of study treatment was included (except that an event that was ongoing at the same grade from before start of study treatment was excluded). Adverse events consisted of Grade ≥ 2 primary diagnosis, primary sign/symptoms, and primary laboratory abnormality. It also included any serious adverse event according to ICH criteria and any treatment-limiting AE (ie, an AE reported as the reason for permanent discontinuation of study treatment). A two-sided 90% confidence interval was calculated for the percentage using the Blyth-Still-Casella method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Had HCV Virologic Relapse | From end of study treatment through to 24 weeks after end of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | HCV virologic relapse was defined as HCV RNA undetectable at end-of-treatment but HCV RNA quantifiable during follow-up with subsequent confirmation as quantifiable. |
| Percentage of HCV Virologic Failure Participants That Developed SOF- or LDV-Associated Resistance Mutations | At time of HCV virologic failure; any time from start of study treatment to 24 weeks after end of study treatment. Duration of study treatment for Cohort 1 and 2 were 12 and 8 weeks, respectively. | Percentage of participants who developed SOF- or LDV-associated resistance mutation found within HCV Virologic Failure participants. HCV virologic failure was defined as HCV RNA undetectable at end-of-treatment but HCV RNA quantifiable during follow-up with subsequent confirmation as quantifiable. |
| Count and Percentage of Participants With an Adverse Event by Type. | Any time from start of treatment to 28 days after date of last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | The adverse events considered were Grade 2 or higher adverse events (primary diagnosis, primary sign and symptom, or a primary lab), SAE according to ICH criteria, or treatment-limiting adverse events. Participants may experience more than one type of adverse event. |
| Count of Participants With HIV-1 RNA <50 Copies/mL | 4 and 12 weeks after start of study treatment for Cohort 1. 4 and 8 weeks after start of study treatment for the 8-week regimen used in Cohort 2) | Because all except one participant had HIV-1 RNA \< 50 copies/mL, participants were categorized according to whether or not their HIV-1 RNA was \<5 copies/mL at each follow-up evaluation. |
| Change in CD4+ Cell Count | Baseline to 12 weeks after end of study treatment. Duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | The change in CD4+ cell count from baseline to 12 weeks after the end of study treatment. |
| Self-reported Adherence to SOF | 1, 2, 4, 8 and 12 weeks after starting study treatment. | Count and percentage of participants who reported having taken all doses of SOF. This outcome measure was evaluated in Cohort 1 only. |
| Adherence as Measured by SOF Pill Count | 12 weeks after starting study treatment. | The count and percentage of participants who had a pill count consistent with 100% of SOF doses taken. This outcome measure was evaluated in Cohort 1 only. |
| Percentage of Participants With HCV RNA Undetectable During Study Treatment | 1, 2, 4, 8 and, for the 12-week regimen, 12 weeks after starting study treatment. | HCV RNA undetectable was defined as an HCV RNA measurement \<LLOQ, TND. If there was no measurement at a scheduled time, then the participant was considered as having detectable HCV RNA at that time, unless both the preceding and succeeding measurements were undetectable. A two-sided 90% confidence interval was calculated for each proportion using the Blyth-Still-Casella method. |
| Adherence as Measured by RBV Pill Count | 12 weeks after starting study treatment. | The count and percentage of participants who had a pill count consistent with 100% of RBV doses taken. This outcome measure was evaluated in Cohort 1 only. |
| Self-reported Adherence to LDV/SOF | 1, 2, 4, and 8 weeks after starting study treatment. | Count and percentage of participants who reported having taken all doses of LDV/SOF. This outcome measure was evaluated in Cohort 2 only. |
| Adherence as Measured by LDV/SOF Pill Count | 8 weeks after starting study treatment. | The count and percentage of participants who had a pill count consistent with 100% of LDV/SOF doses taken.. This outcome measure was evaluated in Cohort 2 only. |
| Ribavirin Concentration in Plasma | 4, 8, and 12 weeks after starting study treatment. | Ribavirin concentration in plasma. This outcome was evaluated in Cohort 1 only. |
| Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | Baseline (before HCV study treatment), EOT (end of trial dosing), 12 weeks after end of HCV study treatment. The duration of HCV study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | Cellular concentration of tenofovir diphosphate (TFV-DP) from dried blood spot samples. |
| Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) | Baseline (before SOF + RBV dosing), EOT (end of study treatment), 12 weeks after end of HCV study treatment. | Concentration of tenofovir diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs). This outcome is measured in Cohort 1 only. |
| Concentration of Tenofovir (TFV) in Plasma | Baseline (before HCV study treatment), EOT (end of trial dosing), 12 weeks after end of HCV study treatment. The duration of HCV study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | Concentration of tenofovir (TFV) in plasma among participants who took TFV for treatment of HIV infection. |
| Self-reported Adherence to RBV | 1, 2, 4, 8 and 12 weeks after starting study treatment. | Count and percentage of participants who reported having taken all doses of RBV. This outcome measure was evaluated in Cohort 1 only. |
| Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | 2, 4, 8 and 24 weeks after last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively. | HCV RNA undetectable is defined as an HCV RNA measurement \<LLOQ, TND. If there was no measurement at a scheduled time, then the participant was considered as having detectable HCV RNA at that time, unless both the preceding and succeeding measurements were undetectable. This outcome measure was referred to as SVR2, SVR4, SVR8 and SVR24 where SVR means sustained virologic response. A two-sided 90% confidence interval was calculated for the percentage using the Blyth-Still-Casella method. |
Countries
United States
Participant flow
Recruitment details
Participants were enrolled at 12 different study sites in the United States. For Cohort 1, the first participant enrolled on 30 May 2014; the last participant enrolled on 7 October 2014. For Cohort 2, the first participant enrolled on 31 August 2015; the last participant enrolled on 27 September 2015.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks Follow-up occurred through to 24 weeks after the end of treatment.
Sofosbuvir (SOF): Participants received one 400 mg tablet of sofosbuvir orally every morning with food.
Ribavirin(RBV): Participants received weight-based RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management. | 17 |
| Cohort 2: LDV/SOF for 8 Wks Follow-up occurred through to 24 weeks after the end of treatment.
Ledipasvir/Sofosbuvir (LDV/SOF): Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of LDV and 400 mg of SOF. | 27 |
| Total | 44 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 1 |
Baseline characteristics
| Characteristic | Cohort 1: SOF+Weight-based RBV for 12 Wks | Cohort 2: LDV/SOF for 8 Wks | Total |
|---|---|---|---|
| Age, Continuous | 45 Years | 46 Years | 45.5 Years |
| Age, Customized Age 20-29 years | 3 Participants | 1 Participants | 4 Participants |
| Age, Customized Age 30-39 years | 1 Participants | 8 Participants | 9 Participants |
| Age, Customized Age 40-49 years | 10 Participants | 10 Participants | 20 Participants |
| Age, Customized Age 50-59 years | 2 Participants | 6 Participants | 8 Participants |
| Age, Customized Age 60-69 years | 1 Participants | 1 Participants | 2 Participants |
| Age, Customized Age 70+ years | 0 Participants | 1 Participants | 1 Participants |
| HCV Genotype 1a | 11 Participants | 23 Participants | 34 Participants |
| HCV Genotype 1b | 2 Participants | 3 Participants | 5 Participants |
| HCV Genotype 1 (subtype unknown) | 2 Participants | 0 Participants | 2 Participants |
| HCV Genotype 2b | 1 Participants | 0 Participants | 1 Participants |
| HCV Genotype 4 | 0 Participants | 1 Participants | 1 Participants |
| HCV Genotype Indeterminate | 1 Participants | 0 Participants | 1 Participants |
| HCV RNA | 2280000 IU/mL | 1490000 IU/mL | 1500000 IU/mL |
| HCV RNA Levels < 6 million IU/mL | 15 Participants | 21 Participants | 36 Participants |
| HCV RNA Levels >= 6 million IU/mL | 2 Participants | 6 Participants | 8 Participants |
| History of Sexually Transmitted Infections No History of STI Diagnosis | 9 Participants | 16 Participants | 25 Participants |
| History of Sexually Transmitted Infections Reported History of STI Diagnosis | 8 Participants | 11 Participants | 19 Participants |
| HIV RNA <50 copies/mL | 15 Participants | 27 Participants | 42 Participants |
| HIV RNA >= 50 copies/mL | 1 Participants | 0 Participants | 1 Participants |
| IL28B Genotype CC | 4 Participants | 16 Participants | 20 Participants |
| IL28B Genotype CT | 10 Participants | 7 Participants | 17 Participants |
| IL28B Genotype TT | 3 Participants | 4 Participants | 7 Participants |
| Intravenous Drug History Currently | 0 Participants | 1 Participants | 1 Participants |
| Intravenous Drug History Never | 13 Participants | 22 Participants | 35 Participants |
| Intravenous Drug History Previously | 4 Participants | 4 Participants | 8 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Asian, Pacific Islander | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Black Non-Hispanic | 0 Participants | 5 Participants | 5 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Hispanic (Regardless of Race) | 11 Participants | 9 Participants | 20 Participants |
| Race/Ethnicity, Customized Race/Ethnicity White Non-Hispanic | 6 Participants | 11 Participants | 17 Participants |
| Received HIV ARVs Prior to Study Entry No | 1 Participants | 0 Participants | 1 Participants |
| Received HIV ARVs Prior to Study Entry Yes | 16 Participants | 27 Participants | 43 Participants |
| Region of Enrollment United States | 17 Participants | 27 Participants | 44 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 17 Participants | 27 Participants | 44 Participants |
| Type of Acute HCV Infection New Infection | 17 Participants | 22 Participants | 39 Participants |
| Type of Acute HCV Infection Reinfection | 0 Participants | 5 Participants | 5 Participants |
| Weight Greater than or equal to 75 kg | 10 Participants | 15 Participants | 25 Participants |
| Weight Less than 75 kg | 7 Participants | 12 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 17 | 0 / 27 |
| other Total, other adverse events | 17 / 17 | 24 / 27 |
| serious Total, serious adverse events | 0 / 17 | 2 / 27 |
Outcome results
Primary
Percentage of Participants With an Occurrence of a Grade ≥ 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE.
Any adverse event occurring after initiation of study treatment through to 28 days after the date of last dose of study treatment was included (except that an event that was ongoing at the same grade from before start of study treatment was excluded). Adverse events consisted of Grade ≥ 2 primary diagnosis, primary sign/symptoms, and primary laboratory abnormality. It also included any serious adverse event according to ICH criteria and any treatment-limiting AE (ie, an AE reported as the reason for permanent discontinuation of study treatment). A two-sided 90% confidence interval was calculated for the percentage using the Blyth-Still-Casella method.
Time frame: From initiation of study treatment to 28 days after last dose of study treatment. The duration for study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who enrolled and started first dose of study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With an Occurrence of a Grade ≥ 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE. | 47.1 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With an Occurrence of a Grade ≥ 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE. | 33.3 Percentage of participants |
Primary
Percentage of Participants With Sustained Virologic Response 12 (SVR12)
SVR12 was defined as HCV RNA undetectable less than the lower limit of quantification, Target Not Detected (\<LLOQ TND) of the assay at 12 weeks after date of last dose of study treatment. For both Cohort 1 and Cohort 2, the 12 week measurement used for determining SVR12 was the measurement obtained closest to 84 days (i.e. 12\*7 days), within the window 79 to 112 days inclusive. If a participant did not have an HCV RNA measurement within this window, then the participant was considered as having detectable HCV RNA at 12 weeks unless the preceding and subsequent HCV RNA measurements were both undetectable (\<LLOQ TND). A two-sided 90% confidence interval was calculated for this percentage using the Blyth-Still-Casella method.
Time frame: At 12 weeks after date of last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who enrolled and started at least one dose of study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With Sustained Virologic Response 12 (SVR12) | 58.8 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With Sustained Virologic Response 12 (SVR12) | 100.0 Percentage of participants |
Secondary
Adherence as Measured by LDV/SOF Pill Count
The count and percentage of participants who had a pill count consistent with 100% of LDV/SOF doses taken.. This outcome measure was evaluated in Cohort 2 only.
Time frame: 8 weeks after starting study treatment.
Population: Participants in Cohort 2 who successfully enrolled and received first dose of LDV/SOF.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 2: LDV/SOF for 8 Wks | Adherence as Measured by LDV/SOF Pill Count | Pill count not available | 7 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Adherence as Measured by LDV/SOF Pill Count | Pill count consistent with 100% of doses taken | 17 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Adherence as Measured by LDV/SOF Pill Count | Pill count indicates <100% of doses taken | 3 Participants |
Secondary
Adherence as Measured by RBV Pill Count
The count and percentage of participants who had a pill count consistent with 100% of RBV doses taken. This outcome measure was evaluated in Cohort 1 only.
Time frame: 12 weeks after starting study treatment.
Population: Participants in Cohort 1 who successfully enrolled and received first dose of SOF + weight-based RBV.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Adherence as Measured by RBV Pill Count | Pill count not available | 12 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Adherence as Measured by RBV Pill Count | Pill count consistent with 100% of doses taken | 1 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Adherence as Measured by RBV Pill Count | Pill count indicates <100% of doses taken | 4 Participants |
Secondary
Adherence as Measured by SOF Pill Count
The count and percentage of participants who had a pill count consistent with 100% of SOF doses taken. This outcome measure was evaluated in Cohort 1 only.
Time frame: 12 weeks after starting study treatment.
Population: Participants in Cohort 1 who successfully enrolled and received first dose of SOF+weight-based RBV.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Adherence as Measured by SOF Pill Count | Pill count not available | 12 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Adherence as Measured by SOF Pill Count | Pill count consistent with 100% of doses taken | 4 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Adherence as Measured by SOF Pill Count | Pill count indicates <100% of doses taken | 1 Participants |
Secondary
Cellular Concentration of Tenofovir Diphosphate (TFV-DP)
Cellular concentration of tenofovir diphosphate (TFV-DP) from dried blood spot samples.
Time frame: Baseline (before HCV study treatment), EOT (end of trial dosing), 12 weeks after end of HCV study treatment. The duration of HCV study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who started first dose of study treatment and also took tenofovir disoporxil fumarate (TDF) for treatment of HIV infection.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | Baseline | 1687 fmol/punch | Geometric Coefficient of Variation 30.7 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | End of treatment | 6607 fmol/punch | Geometric Coefficient of Variation 73.8 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | 12 Weeks after end of HCV study treatment | 2100 fmol/punch | Geometric Coefficient of Variation 36.4 |
| Cohort 2: LDV/SOF for 8 Wks | Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | End of treatment | 26846 fmol/punch | Geometric Coefficient of Variation 49.3 |
| Cohort 2: LDV/SOF for 8 Wks | Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | Baseline | 1516 fmol/punch | Geometric Coefficient of Variation 36.2 |
| Cohort 2: LDV/SOF for 8 Wks | Cellular Concentration of Tenofovir Diphosphate (TFV-DP) | 12 Weeks after end of HCV study treatment | 1644 fmol/punch | Geometric Coefficient of Variation 54.6 |
Secondary
Change in CD4+ Cell Count
The change in CD4+ cell count from baseline to 12 weeks after the end of study treatment.
Time frame: Baseline to 12 weeks after end of study treatment. Duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who successfully enrolled and recieved first dose of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Change in CD4+ Cell Count | 11 cells/mm^3 | Standard Deviation 111 |
| Cohort 2: LDV/SOF for 8 Wks | Change in CD4+ Cell Count | 61 cells/mm^3 | Standard Deviation 125 |
Secondary
Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs)
Concentration of tenofovir diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs). This outcome is measured in Cohort 1 only.
Time frame: Baseline (before SOF + RBV dosing), EOT (end of study treatment), 12 weeks after end of HCV study treatment.
Population: Participants in Cohort 1 who successfully enrolled and received first dose of SOF + weight-based RBV and who were also taking tenofovir disoproxil fumarate (TDF) for treatment of HIV infection.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) | Baseline | 79 fmol/10^6 cells | Geometric Coefficient of Variation 47.9 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) | End of treatment | 149 fmol/10^6 cells | Geometric Coefficient of Variation 91.3 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) | 12 Weeks after end of HCV study treatment | 81 fmol/10^6 cells | Geometric Coefficient of Variation 54.4 |
Secondary
Concentration of Tenofovir (TFV) in Plasma
Concentration of tenofovir (TFV) in plasma among participants who took TFV for treatment of HIV infection.
Time frame: Baseline (before HCV study treatment), EOT (end of trial dosing), 12 weeks after end of HCV study treatment. The duration of HCV study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who started first dose of study treatment and also took tenofovir (TFV) for treatment of HIV infection.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Concentration of Tenofovir (TFV) in Plasma | Baseline | 98 ng/mL | Geometric Coefficient of Variation 62.6 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Concentration of Tenofovir (TFV) in Plasma | End of treatment | 96 ng/mL | Geometric Coefficient of Variation 57.2 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Concentration of Tenofovir (TFV) in Plasma | 12 Weeks after end of HCV study treatment | 94 ng/mL | Geometric Coefficient of Variation 75.7 |
| Cohort 2: LDV/SOF for 8 Wks | Concentration of Tenofovir (TFV) in Plasma | Baseline | 87 ng/mL | Geometric Coefficient of Variation 97.6 |
| Cohort 2: LDV/SOF for 8 Wks | Concentration of Tenofovir (TFV) in Plasma | End of treatment | 155 ng/mL | Geometric Coefficient of Variation 112.1 |
| Cohort 2: LDV/SOF for 8 Wks | Concentration of Tenofovir (TFV) in Plasma | 12 Weeks after end of HCV study treatment | 76 ng/mL | Geometric Coefficient of Variation 66.2 |
Secondary
Count and Percentage of Participants With an Adverse Event by Type.
The adverse events considered were Grade 2 or higher adverse events (primary diagnosis, primary sign and symptom, or a primary lab), SAE according to ICH criteria, or treatment-limiting adverse events. Participants may experience more than one type of adverse event.
Time frame: Any time from start of treatment to 28 days after date of last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who successfully enrolled and received first dose of treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Treatment-Limiting Adverse Event | 0 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Primary Sign/Symptom | 5 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Primary Lab | 5 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Serious Adverse Event | 0 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Primary Diagnosis | 0 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Serious Adverse Event | 1 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Treatment-Limiting Adverse Event | 0 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Primary Diagnosis | 2 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Primary Lab | 6 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count and Percentage of Participants With an Adverse Event by Type. | Primary Sign/Symptom | 4 Participants |
Secondary
Count of Participants With HIV-1 RNA <50 Copies/mL
Because all except one participant had HIV-1 RNA \< 50 copies/mL, participants were categorized according to whether or not their HIV-1 RNA was \<5 copies/mL at each follow-up evaluation.
Time frame: 4 and 12 weeks after start of study treatment for Cohort 1. 4 and 8 weeks after start of study treatment for the 8-week regimen used in Cohort 2)
Population: Participants who enrolled successfully, received HIV ARV regimen at entry and started first dose of treatment
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 4 | ≥50 copies/mL | 0 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 4 | <50 copies/mL | 17 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 8 | ≥50 copies/mL | 0 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 8 | <50 copies/mL | 0 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 12 | ≥50 copies/mL | 0 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 12 | <50 copies/mL | 17 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 12 | ≥50 copies/mL | 0 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 4 | ≥50 copies/mL | 0 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 8 | <50 copies/mL | 23 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 4 | <50 copies/mL | 27 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 12 | <50 copies/mL | 0 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Count of Participants With HIV-1 RNA <50 Copies/mL | On-treatment Week 8 | ≥50 copies/mL | 0 Participants |
Secondary
Number of Participants Who Had HCV Virologic Relapse
HCV virologic relapse was defined as HCV RNA undetectable at end-of-treatment but HCV RNA quantifiable during follow-up with subsequent confirmation as quantifiable.
Time frame: From end of study treatment through to 24 weeks after end of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who successfully enrolled and started first dose of treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Number of Participants Who Had HCV Virologic Relapse | 7 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Number of Participants Who Had HCV Virologic Relapse | 0 Participants |
Secondary
Percentage of HCV Virologic Failure Participants That Developed SOF- or LDV-Associated Resistance Mutations
Percentage of participants who developed SOF- or LDV-associated resistance mutation found within HCV Virologic Failure participants. HCV virologic failure was defined as HCV RNA undetectable at end-of-treatment but HCV RNA quantifiable during follow-up with subsequent confirmation as quantifiable.
Time frame: At time of HCV virologic failure; any time from start of study treatment to 24 weeks after end of study treatment. Duration of study treatment for Cohort 1 and 2 were 12 and 8 weeks, respectively.
Population: Participants who observed an HCV virologic failure after successfully enrolling for first dose of treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of HCV Virologic Failure Participants That Developed SOF- or LDV-Associated Resistance Mutations | 0.00 Percentage of participants |
Secondary
Percentage of Participants With HCV RNA Undetectable After End of Study Treatment
HCV RNA undetectable is defined as an HCV RNA measurement \<LLOQ, TND. If there was no measurement at a scheduled time, then the participant was considered as having detectable HCV RNA at that time, unless both the preceding and succeeding measurements were undetectable. This outcome measure was referred to as SVR2, SVR4, SVR8 and SVR24 where SVR means sustained virologic response. A two-sided 90% confidence interval was calculated for the percentage using the Blyth-Still-Casella method.
Time frame: 2, 4, 8 and 24 weeks after last dose of study treatment. The duration of study treatment for Cohort 1 and Cohort 2 were 12 and 8 weeks, respectively.
Population: Participants who successfully enrolled and started first dose of treatment.~Note that one participant in Cohort 2 was lost to follow-up prior to week 24 and is imputed as not having SVR24 at week 24. This participant, however, had HCV RNA \< LLOQ, TND at all moments from week 4 of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR2 | 64.7 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR4 | 58.8 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR8 | 58.8 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR24 | 64.7 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR24 | 96.3 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR2 | 100.0 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR8 | 96.3 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable After End of Study Treatment | SVR4 | 96.3 Percentage of participants |
Secondary
Percentage of Participants With HCV RNA Undetectable During Study Treatment
HCV RNA undetectable was defined as an HCV RNA measurement \<LLOQ, TND. If there was no measurement at a scheduled time, then the participant was considered as having detectable HCV RNA at that time, unless both the preceding and succeeding measurements were undetectable. A two-sided 90% confidence interval was calculated for each proportion using the Blyth-Still-Casella method.
Time frame: 1, 2, 4, 8 and, for the 12-week regimen, 12 weeks after starting study treatment.
Population: Participants who successfully enrolled and started first dose of treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On Treatment Week 2 | 29.4 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 8 | 100.0 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 4 | 70.6 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 12 | 100.0 Percentage of participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 1 | 11.8 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 12 | NA Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 1 | 18.5 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On Treatment Week 2 | 44.4 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 4 | 81.5 Percentage of participants |
| Cohort 2: LDV/SOF for 8 Wks | Percentage of Participants With HCV RNA Undetectable During Study Treatment | On-treatment Week 8 | 92.6 Percentage of participants |
Secondary
Ribavirin Concentration in Plasma
Ribavirin concentration in plasma. This outcome was evaluated in Cohort 1 only.
Time frame: 4, 8, and 12 weeks after starting study treatment.
Population: Participants in Cohort 1 who successfully enrolled and received first dose of SOF + weight-based RBV.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Ribavirin Concentration in Plasma | Week 4 | 1803 ng/mL | Geometric Coefficient of Variation 45.6 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Ribavirin Concentration in Plasma | week 8 | 2122 ng/mL | Geometric Coefficient of Variation 30 |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Ribavirin Concentration in Plasma | Week 12 | 2013 ng/mL | Geometric Coefficient of Variation 36.4 |
Secondary
Self-reported Adherence to LDV/SOF
Count and percentage of participants who reported having taken all doses of LDV/SOF. This outcome measure was evaluated in Cohort 2 only.
Time frame: 1, 2, 4, and 8 weeks after starting study treatment.
Population: Participants in Cohort 2 who successfully enrolled and received first dose of LDV/SOF.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 2: LDV/SOF for 8 Wks | Self-reported Adherence to LDV/SOF | Week 8 | 18 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Self-reported Adherence to LDV/SOF | Week 1 | 25 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Self-reported Adherence to LDV/SOF | Week 2 | 25 Participants |
| Cohort 2: LDV/SOF for 8 Wks | Self-reported Adherence to LDV/SOF | Week 4 | 27 Participants |
Secondary
Self-reported Adherence to RBV
Count and percentage of participants who reported having taken all doses of RBV. This outcome measure was evaluated in Cohort 1 only.
Time frame: 1, 2, 4, 8 and 12 weeks after starting study treatment.
Population: Participants in Cohort 1 who successfully enrolled and received first dose of SOF+weight-based RBV.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to RBV | Week 1 | 16 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to RBV | Week 2 | 15 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to RBV | Week 4 | 15 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to RBV | Week 8 | 16 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to RBV | Week 12 | 15 Participants |
Secondary
Self-reported Adherence to SOF
Count and percentage of participants who reported having taken all doses of SOF. This outcome measure was evaluated in Cohort 1 only.
Time frame: 1, 2, 4, 8 and 12 weeks after starting study treatment.
Population: Participants in Cohort 1 who successfully enrolled and received first dose of SOF+weight-based RBV.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to SOF | Week 1 | 17 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to SOF | Week 2 | 16 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to SOF | Week 4 | 16 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to SOF | Week 8 | 16 Participants |
| Cohort 1: SOF+Weight-based RBV for 12 Wks | Self-reported Adherence to SOF | Week 12 | 15 Participants |